Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

A new study explores the "drusen ooze" hypothesis, revealing how drusen can regress without atrophy in age-related macular degeneration.

We ask leading experts in the field what eye disease they would cure and why.

An expert discusses how she managed an unusual case of a patient with high myopia with angle closure and elevated intraocular pressure (IOP) through cataract extraction with toric lens implantation, combined with canaloplasty and endocyclophotocoagulation (ECP) to address both the refractive needs and anatomical causes of the condition.

A panelist discusses how the iDose implant is surgically placed into the scleral wall with precision, can be repositioned if needed, and remains stable even after procedures like goniotomy, making it a versatile option in glaucoma care.

An expert discusses how she treated a 70-year-old patient with high myopia with mild glaucoma and cataracts using a light adjustable lens combined with an iDose travoprost sustained-release implant to achieve spectacle-free and drop-free outcomes while maintaining excellent pressure control.

A panelist discusses how procedural pharmaceuticals like Durysta and iDose offer sustained drug delivery solutions tailored to patient needs, providing long-term efficacy and reducing dependence on daily eye drops.

A panelist discusses how interventional glaucoma emphasizes early, proactive treatment strategies to reduce IOP and medication burden while addressing patient adherence and long-term disease control.

An expert discusses how modern glaucoma treatment has evolved from a reactive one-size-fits-all approach of multiple drops followed by major surgery to a proactive, individualized strategy that emphasizes early procedural interventions to minimize medication burden and vision loss.

Bausch + Lomb reveals promising results for the enVista Envy IOL, showcasing superior vision outcomes in cataract surgery patients.

OpZira’s product portfolio includes AdaptDx Pro and the NOVA Vision Testing System.